98%
921
2 minutes
20
Background: There is still no consensus on simple methods to monitor the effectiveness of gonadotropin-releasing hormone analogs in girls with precocious or early puberty.
Objective: To evaluate the value of urinary luteinizing hormone (LH) and follicle-stimulating hormone (FSH) before and after triptorelin stimulation test detected by immunochemiluminometric assay (ICMA) to monitor the efficacy of triptorelin depot in girls with precocious or early puberty.
Methods: A total of 128 girls with precocious or early puberty were included, of whom 81 received triptorelin depot treatment (3.75 mg). Triptorelin (100 μg) stimulation tests were performed before and after 3 months treatment. The time of triptorelin stimulation test was designated as 0 h. Timed 12 h urine with recorded urine volume was collected before and after the test, defined as diurnal spontaneous (-24 h to -12 h), nocturnal spontaneous (-12 h to 0 h), diurnal stimulated (0 h to 12 h), and nocturnal stimulated urine (12 h to 24 h), respectively. LH and FSH were assayed by ICMA.
Results: After 3 months of treatment, 67 girls completed sample collections, with 2 out of 67 girls experiencing inadequate efficacy. Serum and urinary gonadotropin levels decreased significantly after 3 months of treatment. The area under curve (AUC) of nocturnal spontaneous, diurnal stimulated, and nocturnal stimulated urinary FSH (UFSH) concentrations in determining efficacy were 0.962, 0.985, and 0.954. The three AUCs were all greater than serum peak LH (PLH, 0.746) or peak FSH (PFSH, 0.931). When nocturnal spontaneous, diurnal stimulated, and nocturnal stimulated UFSH concentrations were ≤ 5.24 IU/L, 6.94 IU/L, and 5.78 IU/L, the sensitivity was 93.8 %, 96.9 % and 95.4 %, and the specificity was all 100.0 %.
Conclusion: UFSH measured by ICMA from diurnal and nocturnal stimulated 12-hour urine samples can be used to assess the effectiveness of triptorelin depot in girls with precocious or early puberty. For a non-invasive and cost-effective option, spontaneous nocturnal urine may also be a suitable choice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arcped.2025.06.003 | DOI Listing |
Front Pediatr
August 2025
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.
Methods: This was a hospital data-based retrospective study.
Ann Pediatr Endocrinol Metab
August 2025
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.
View Article and Find Full Text PDFAnn Pediatr Endocrinol Metab
August 2025
Department of Pediatrics, Inje University Sanggye Paik Hospital, Inje University School of Medicine, Seoul, Korea.
Breast Cancer Res
September 2025
Department of Maternal, Child and Adolescent Health, School of Public Health, Ministery of Education Key Laboratory of Population Health Across Life Cycle, Anhui Medical University, Hefei, Anhui, China.
Background: The age of thelarche in girls has declined globally. While earlier menarche has been linked to higher breast density - a known risk factor for breast cancer - the association between earlier thelarche and breast density remains unclear.
Methods: 114 Girls presenting with idiopathic central precocious puberty without medication (ICPP), early thelarche (ET), and normal age at thelarche (NT) were recruited from pediatric endocrine clinics of three hospitals during the year of 2020-2021 in Hefei, Anhui Province, China and were followed up for 3-5 years.
Sci Rep
August 2025
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
The Chinese Expert Consensus on central precocious puberty (CPP) defines girls' rapid sexual development before age 8 as CPP; while after age 8 as early normal puberty (ENP). And the use of recombinant human growth hormone (rhGH) for CPP and ENP is off-label and lacks reliable evidence for clinical practice. This study only included girls due to the low prevalence among boys.
View Article and Find Full Text PDF